MassArray and Related Sales Push Sequenom's Q1 Revenues up 43 Percent | GenomeWeb
NEW YORK (GenomeWeb News) - Sequenom yesterday said first-quarter revenue surged 43 percent as R&D spending increased 17 percent and net loss was stable. 
 
Total receipts for the three months ended March 31, 2007, rose to $9.9 million from $6.9 million year over year.
 
The company said the jump in revenues was driven mainly by sales of MassArray instruments and related products, and by growth in its contract research services group.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.